key: cord-0751494-tz0pgml3
authors: Ariza, B. E.; Torres, Y. X.; Salgado, D.; Cepeda, M.; Gomez, C.; Castellanos, J. C.; Suarez, F.; Cuellar, A.; Cardozo, C. C.; Angel, J.; Franco, M. A.
title: Seroprevalence and seroconversion rates to SARS-CoV-2 in interns, residents, and medical doctors in a University Hospital in Bogota, Colombia
date: 2020-09-18
journal: nan
DOI: 10.1101/2020.09.15.20195313
sha: 3669cf084358c7b6351491c27ee97c67bd0aa9bd
doc_id: 751494
cord_uid: tz0pgml3

Objectives To determine the prevalence of antibodies to SARS-CoV-2 and the incidence of seroconversion in the first month of follow-up among interns, residents, and medical doctors attending patients at a University Hospital, to explore for associations of seroprevalence and seroconversion with risk factors and symptoms compatible with COVID-19, and to explore the concordance of CLA, LFA, and ELFA. Design or methods We conducted a cross-sectional and a prospective study among medical doctors and medical trainees at Hospital Universitario San Ignacio in Bogota (Colombia) during June, July, and August to assess seroprevalence and seroconversion rates in this population was performed using CLA IgG for SARS-CoV-2. LFA IgG and IgM and ELFA IgM were also determined to explore concordance with CLA IgG. Results At baseline, 8 (2.28% 95%CI 1.16-4.43%) individuals were IgG positive for SARS-CoV-2 by CLA. At the end of the study, 21 (5.98% 95%CI 3.94-8.97%) individuals seroconverted by CLA IgG. In all, 29 individuals had IgG by CLA and of these 11 (3.13% 95%CI 1.76-5.52%) were asymptomatic. No associations with risk factors for infection were identified. CLA had moderate concordance with LFA IgG and ELFA, but minimal with LFA IgM. Conclusions Our report is one of the first in Latina America on seroprevalence and seroconversion rates in medical healthcare workers. It emphasizes the importance of avoiding focusing only on symptomatic individuals to screen this population for SARS-CoV-2 infection, since of all individuals that have evidence of previous infection many (37.93%) may be pre-symptomatic or asymptomatic and may contribute to infection/disease spread.

Latin America was one of the most severely compromised regions of the world during the SARS-CoV-2 pandemic, between June and August 2020.

Healthcare workers are at increased risk for COVID-19 and studies of seroprevalence and seroconversion rates in these subjects have not been published in the area.

We conducted a cross-sectional and prospective study of medical doctors and medical trainees in a University Hosptial during June, July, and August 2020 to assess seroprevalence and seroconversion rates of SARS-CoV-2 in this population, using a Chemiluminescent assay (CLA). In all, 29 (8.26% 95%CI 5.81-11.61%) individuals had IgG for SARS-CoV-2 by CLA and of these 11 (3.13% 95%CI 1.76-5.52%) were asymptomatic.

Our report is one of the first in Latina America on seroprevalence and seroconversion rates in medical healthcare workers. It emphasizes the importance of avoiding focusing only on symptomatic individuals to screen this population for SARS-CoV-2 infection, since of all individuals that have evidence of previous infection many (37.93%) may be pre-symptomatic or asymptomatic and may contribute to infection/disease spread.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

During the SARS-CoV-2 pandemic healthcare workers (HCW) have been shown to have an increased risk of infection [1] [2] [3] [4] [5] [6] . Studies in this population in many parts of the world have shown seroprevalences of between 2.4% and 45%, and in general above that of the general population and varing according to multiple factors [1] [2] [3] [4] [5] [6] . In asymptomatic HCW, at the peak of the pandemic in England, a global seroprevalence rate of 24.4% was found [7] . Furthermore, individuals who retrospectively reported symptoms compatible with COVID-19 had a higher seroprevalence rate than those who did not report them, in this study and other studies [6, 7] . Although retrospective reporting of symptoms may have evocation bias, these findings indicates that, in the context of COVID-19 a relationship can be established between retrospectively reported symptoms and seroprevalence. Seroconversion rates in HCW have been reported in fewer studies and varied between 20-44% in short term followup during high circulation of SARS-CoV-2 [1, 8] .

Latin-America is one of the most affected regions of the world by the pandemic [9] , with peak cases occurring between July 20 and August 16 [10] . Although some studies from Latin-American countries evaluating serology in the general population [11, 12] or schools have been published [13, 14] , to our knowledge only one study in an oncology unit in Brazil [15] has assessed seroprevalence in HCW. Our study was performed during a very active increase of SARS-CoV-2 infections in our country and city: during the five weeks of the study 248,205 new cases were identified in Colombia (109, 505 vs. 357, 710) and 93,907 of these were in Bogotá (34, 131 vs. 128, 038) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 18, 2020. . (http://saludata.saludcapital.gov.co/osb/index.php/datos-de-salud/enfermedadestrasmisibles/covid19/ page consulted 08 /19/20) . Records from our hospital (Hospital Universitario San Ignacio (HUSI)) show that during June-August the adult intensive care unit (28 beds in June and 32 beds in July and August) was at full (100%) occupancy with presumed or confirmed COVID-19 patients.

The main purpose of this study was to determine the prevalence of antibodies, and the seroconversion rates to SARS-CoV-2 in a month of follow-up of interns, residents, and medical doctors of the School of Medicine of the Pontificia Universidad Javeriana attending patients at HUSI.

A) Study design: First, a cross-sectional study was conducted to determine the seroprevalence of SARS-CoV-2 infection in study population (interns, residents, and medical doctors that were treating patients at HUSI at the time of the study). Potential candidates were invited to participate by email. Potential participants who were not attending patients at HUSI in June and July and who were taking immunosuppressive drugs (chloroquine, corticosteroids, etc.) were excluded from the study (Figure 1 ). The remaining participants were asked to fill out a survey about risk factors and symptoms associated with COVID-19, history of previous diagnosis of COVID -19 confirmed by PCR or of clinically diagnosed COVID-19 supported by the presence of . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 18, 2020. . SARS-CoV-2 antibodies. The survey was designed in RedCap (Research Electronico Data capture [16] ).

In a second step, a prospective study was conducted to determine the incidence of seroconversion two weeks and a month of follow-up after baseline visit among the seronegative individuals from the cross-sectional study.

As secondary objectives, we aimed to assess the relation between seropositivity either at baseline or during follow-up and risk factors and symptoms compatible with COVID-19. Finally, as an exploratory objective, we examined the concordance of CLA IgG as a tempative gold standard with the LFA IgG and IgM and ELFA IgM and concordance of the ELFA IgM and LFA IgM.

At the HUSI's clinical laboratory, individuals updated the survey of clinical symptoms compatible with COVID-19, signed an electronic informed consent, and donated 7 ml of venous blood.

SARS-CoV-2 IgG tests (Abbott Colombia) were performed on an Abbott Architect i1000 analyzer, following the manufacturer's protocol. A single lot of positive and negative controls were run at the start of each batch of antibody testing. Samples with a signalto-cutoff (S/CO) ratio greater than or equal to 1.4 were considered positive.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 18, 2020. .

Gyeonggi-do, Korea) were performed following the manufacturer's protocols. Positive results were determined by the appearance of a visible band in the designated area, simultaneously with an appropriate positive control band.

The VIDAS Anti-SARS CoV-2 IgM two-step sandwich ELFA was performed on a VIDAS analyzer (BioMérieux, Marcy-l'Etoile, France). An index is calculated as the ratio between the relative fluorescence value measured in the sample and the relative fluorescence obtained for a calibrator (humanized recombinant anti-SARS CoV-2 IgM) and interpreted as negative (index<1) or positive (index≥1) [17] .

All assays were validated with serum samples from PCR+/-individuals in our laboratory

Our project complied with the legal and ethical guidelines contemplated in the . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 18, 2020 . .

The data was exported and analyzed in Stata 14. We conducted a descriptive analysis of the demographic characteristics of the study participants, according to the seropositivity. Continuous variables were described using median and interquartile range (percentiles 25th and 75th) and categorical variables were described using absolute and relative frequencies.

Second, we examined the relation between seropositivity either at baseline or during the follow-up and risk factors and symptoms compatible with COVID-19, we estimated the odds ratio and 95% confidence interval using logistic regression Third, we assessed the concordance of CLA IgG, as a tempative gold standard, with LFA IgG and IgM and ELFA IgM, and the concordance of ELFA IgM and LFA IgM, using the Cohen's kappa and the corresponding 95% confidence interval.

Seven hundred and fifty-two (752) medical trainees or medical doctors from HUSI were invited to participate by email ( Figure 1 ). Of these, 428 answered the baseline survey, and it was possible to arrange an appointment to bleed 351 of them ( Figure 1 ). Six individuals reported a previous diagnosis of infection with SARS-CoV-2 confirmed by PCR (all but one with symptoms compatible with COVID-19) and two had been hospitalized with symptoms consistent with COVID-19 and positive SARS-CoV-2 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 18, 2020. . antibodies, but their PCR had not identified SARS-CoV-2 (Tables 1 and 2 and Data not shown).

Individuals in our cohort were bled at baseline between June 25 and the 4 of July. At baseline 8 (2.28% 95%CI 1.16-4.43%) individuals were SARS-CoV-2 IgG positive by CLA (Table 1 and Figure 2 ). For comparison, we also measured IgG and IgM antibodies by LFA ( Table 1 ) and found that six individuals of the eight indivuals were also positive for IgM and IgG by LFA. Of these six individuals, one had COVID-19 compatible symptoms and a previous diagnosis of COVID-19 by PCR, two had previously been hospitalized with clinical diagnosis of COVID-19 (with negative PCR but positive serology), one had a positive PCR but had remained asymptomatic, and two without history of previous SARS-CoV-2 infection were also asymptomatic (Tables 1 and 2 ).

Finally, one asymptomatic and one symptomatic individual were positive for IgG by CLA, but negative for LFA antibodies ( Table 2 ). In addition, 18 individuals were only positive for SARS-CoV-2 LFA IgM and one was only positive for LFA IgG ( Table 1) . One of the 18 individuals that was only positive for IgM had a history of previous COVID-19 symptoms and a positive PCR before joining the study (Tables 1 and 2 ). The majority of individuals (16/18) with only a positive LFA IgM result and tested for SARS-CoV-2 PCR were negative for PCR at a date close to the date when the antibody sample was obtained ( Table 2 ). Somewhat unexpectedly, three of the eight individuals that declared having a positive SARS-CoV-2 PCR previous to the start of the study were negative for all of the antibodies measured (Data not shown).

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 18, 2020. .

A second and third blood samples was taken approximately two weeks ) and one month (28.7 days 95%CI 28.3-29.0) after baseline for each individual, from the 9th-21st of June and from June 23 to August 10, respectively.

Three hundred and thirty-five (335) Figure 2 ). Three of these nine individuals were asymptomatic. None of the previously IgM positive individuals by LFA or the individual that only was IgG positive by LFA seroconverted by CLA IgG (Table 1) (Table 1) , with one individual scoring marginally below the cutoff level of the assay ( Figure 2 ). All nine individuals that seroconverted in IgG CLA in the second bleed remained positive and 12 new individuals (3.93% 95%CI 2.31-6.61%) seroconverted.

Four of the twelve individuals that seroconverted in the last sample were asymptomatic ( Figure 2 ). Thus, adding the 21 individuals that seroconverted with the eight that had IgG . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 18, 2020. . by CLA at baseline, 29 individuals .61%) had SARS-CoV-2 IgG by CLA and of these 11 (3.13% 95%CI 1.76-5.52%) were asymptomatic ( Table 1) .

Demographic, infection risk factors, and prevalence of symptoms compatible with COVID-19 for this population are presented in Table 3 for individuals with or without a positive SARS-CoV-2 CLA test in the study. No risk factors were associated with seroprevalence or seroconversion to SARS-CoV-2.

To further evaluate concordance of the LFA and CLA assays and to extend this analysis to ELFA IgM, thawed samples from the first bleed were tested by ELFA and thawed samples from bleeds 2 and 3 were tested by ELFA IgM and LFA IgG and IgM.

Concordance of CLA IgG with LFA IgG and ELFA IgG was moderate and with LFA IgM, minimal (Table 4 ) [18] . The ELFA IgM and LFA IgM also had minimal concordance (Table 5 ).

We have performed one of the first SARS-CoV-2 seroprevalence/seroconversion rate studies in Latin-America and found that at baseline 2.28% of HCW were IgG positive by CLA (Table 1) . At the end of the study, 5.98% of individuals had seroconverted by CLA . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 18, 2020. . IgG and, in all, 29 individuals (8.26%) had SARS-CoV-2 IgG by CLA, of which 11 (3.13%) were asymptomatic (Table  1) . No associations between seroprevalence/seroconversion in CLA and risk factors for infection were identified.

Concordance of CLA IgG with LFA IgG and ELFA IgG was moderate and with LFA IgM, minimal ( Table 4 ). The ELFA IgM and LFA IgM also had minimal concordance ( Table   5 ).

The levels of seroprevalence for CLA IgG (2.28%) at the beginning of the study and of seroconversion to this antibody (5.98%) are comparable to those reported in other studies and, overall, higher than those observed in the general population [1] [2] [3] [4] [5] [6] . In a comparable study in England that followed 200 front line HCW for two weeks, they found that 20% of them seroconverted during the study, but 25% were already seropositive at the beginning of the study [1] . Most likely, the higher numbers in the English study compared with our study are due to the differences in the populations studied (front line workers vs a mixed population of medical doctors).

One of the main findings of our study, is the relatively high numbers (3.18%) of asymptomatic individuals positive for IgG by CLA (Table 1 ). This number is very close to the number of asymptomatic HCW detected by screening with PCR in nasofaringeal swabs (3%) [19] or saliva (2,6%) [20] in England. Although it is incompletely clear how much pre-symptomatic and asymptomatic individuals contribute to virus spread, focusing only on stopping symptomatic individuals is insufficient to control the spread of the virus [21, 22] . None-invasive rapid screening strategies for SARS-CoV-2 infection are needed to evaluate symptomatic and asymptomatic HCW.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 18, 2020. . The lack of association between risk factors and SARS-CoV-2 seroprevalence/seroconversion in CLA (Table 3 ) may be explained because some of the risk factors evaluated (obesity, diabetes, hypertension, and smoking) can be risk factors for disease and not infection. Moreover, most of the participants used PPE and followed biosafety recommendations (Table 3) .

Our results seem comparable to previous studies in which the CLA test that we used showed a sensitivity and specificity close to 100% when compared with PCR +/samples [23] [24] [25] , while the LFA [26] and the ELFA [17] appear to be less sensitive and (Table 1) .

However, none of these individuals had a positive PCR at or close to the time when the sample was taken (Table 3) . With few exceptions, they did not present with COVID-19

compatible symptoms ( . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted September 18, 2020. . Our study may have a sampling bias. Independent data from our hospital indicate that up to the 15th of June 13 medical doctors and 7 residents from approximately 800 individuals had been diagnosed with COVID-19 (with PCR or clinical symptoms/serology). By the 15 th of August, these numbers had increased to 44 medical doctors and 55 residents diagnosed with COVID-19. These numbers are higher than what we found in our population an suggest that our values of seroprevalence and seroconversion may be underestimated. A probable explanation for this is that volunteers with COVID-19 were isolated at the time of sampling and were unable to participate in the study or that having been previously tested were uninterested in participating.

We want to thank the volunteers that participated and donated blood for this study. We want to thank Dr Pablo Aschner for careful reading and suggestion for the project and Madga Alba and Jenny Severiche for help with the process of recruiting volunteer.

This study was approved by the Ethics Committee of the School of Medicine of Pontificia Universidad Javeriana Bogotá, Colombia and was done in accordance with . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted September 18, 2020. . https://doi.org /10.1101 /10. /2020 The Code of Ethics of the World Medical Association (Declaration of Helsinki). An informed consent form, approved by the Ethics Committee of HUSI and the Pontificia Universidad Javeriana School of Medicine, was signed by all volunteers.

The authors have no conflicts of interest to declare.

This study was funded by Pontificia Universidad Javeriana, Hospital Universitario San Ignacio, and Fundación Bolívar Davivienda.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted September 18, 2020 . . https://doi.org/10.1101 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted September 18, 2020. . . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted September 18, 2020. . Table 1 Antibodies and symptoms of participants with at least one positive antibody results at baseline. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 18, 2020. . Shown are results (PCR) and dates (Date PCR) in which SARS-CoV-PCR was performed prior to each one of the three blood study samples (Date Abs). ND; not done. PCR were not part of the study protocol . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 18, 2020. . but were performed in our Clinical Laboratory from nasopharyngeal aspirates using the VIASURE Real-Time PCR Detection Kit plates (CerTest BIOTEC, Zaragoza, Spain).* PCR reported by participants to have been performed outside of our Clinical Laboratory.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 18, 2020 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 18, 2020. . 24 -34 943 ELFA IgM * 0.6207 95% CI (0.5034-0.7380) + 30 13 -21 941 * Fifteen samples were read as invalid by ELFA and three individuals did not authorize for their sample to be used after the initial test.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 18, 2020. . .

It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review) 

Pandemic peak SARS-CoV-2 infection and seroconversion rates in London frontline health-care workers

Immune response to SARS-CoV-2 in health care workers following a COVID-19 outbreak: a prospective longitudinal study

COVID-19 experience : first Italian survey on healthcare staff members from a Mother-Child Research Hospital using combined molecular and rapid immunoassays test

IgG serology in health care and administrative staff populations from 7 hospitals representative of different exposures to SARS-CoV-2 in

Prevalence of SARS-CoV-2 Antibodies Among Healthcare Workers at a Tertiary Academic Hospital in New York City

Point-of-care serological assays for delayed SARS-CoV-2 case identification among health-care workers in the UK: a prospective multicentre cohort study

SARS-CoV-2 seroconversion in health care workers

Asymptomatic Seroconversion of Immunoglobulins to SARS-CoV-2 in a Pediatric Dialysis Unit

World Health Organization Coronavirus disease (COVID-19)

Epidemiological Highlights -Region of the Americas

Population-based surveys of antibodies against SARS-CoV-2 in Southern Brazil

Community-level SARS-CoV-2 Seroprevalence Survey in urban slum dwellers of

SARS-CoV-2 antibody prevalence in blood in a large school community subject to a Covid-19 outbreak: a cross-sectional study

SeroTracker: a global SARS-CoV-2 seroprevalence dashboard

Universal Screening of SARS-CoV-2 of Oncology Healthcare Work-ers -a Brazilian experience

Research electronic data capture (REDCap)-A metadata-driven methodology and workflow process for providing translational research informatics support

Frédéric Cotton, Montesinos, Monitoring antibody response following SARS-CoV-2 infection: Diagnostic efficiency of four automated immunoassays

Interrater reliability: the kappa statistic

Screening of healthcare workers for SARS-CoV-2 highlights the role of asymptomatic carriage in COVID-19 transmission

Saliva is more sensitive for SARS-CoV-2 detection in COVID-19 patients than nasopharyngeal swabs

Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility

The prominence of asymptomatic superspreaders in transmission mean universal face masking should be part of COVID-19 de-escalation strategies

Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in

Kinetics and performance of the Abbott Architect SARS-CoV-2 IgG antibody assay

Performance evaluation of Abbott ARCHITECT SARS-CoV-2 IgG immunoassay in comparison with indirect immunofluorescence and virus microneutralization test

Validation and Performance 1 Comparison of Three SARS-CoV-2 Antibody Assays